The in vitro activities of two new carboxyquinolones, A-56619 (difloxacin) and A-56620, were compared with those of ciprofloxacin, norfloxacin, and ofloxacin against genital tract pathogens. All the quinolones were highly active against Neisseria gonorrhoeae. A-56619 had the lowest MICs against Chlamydia trachomatis (MIC range, 0.125 to 0.25 ,ug/ml) and Haemophilus ducreyi (MIC for 90% of isolates tested, 0.1 ,ug/ml).
The newer quinolone antimicrobial agents have been shown to have excellent activity in vitro against gonococci, including ,B-lactamase-producing strains (3, 11, 13, 16, 18) , and moderate activity in vitro against Chlamydia trachomatis (2, 10, 14) .
We compared the activities of A-56619 (difloxacin), A-56620, ciprofloxacin, norfloxacin, ofloxacin, and antimicrobial agents now used for the treatment of genital infections against clinical isolates of Neisseria gonorrhoeae, Haemophilus ducreyi, Gardnerella vaginalis, Ureaplasma urealyticum, and C. trachomatis.
Antimicrobial reference standards and sources were as follows: A-56619, A-56620, and erythromycin, Abbott Lab of M. hominis and 2-day-old broth cultures of U. urealyticum were inoculated into 100 ,ul of twice the required final concentration of each of the antibiotic dilutions in U-well microtiter plates. Controls containing medium only, medium plus antimicrobial agent, and medium plus M. hominis or U. urealyticum were included. The microtiter plates were sealed and incubated at 37°C until the indicator in the Mycoplasma-Ureaplasma control well changed color. The MIC was defined as the lowest concentration of antimicrobial agent which prevented color change.
MIC testing of C. trachomatis was performed by a modification of a previously described method (15 With the increasing incidence of infections caused by penicillinase-producing strains of N. gonorrhoeae and gonococci with chromosomal resistance to penicillin and other antimicrobial agents and of mixed infections involving C. trachomatis, it has become necessary to look for new antimicrobial agents for the treatment of sexually transmitted diseases. The carboxyquinolones might fulfill such a role. They are very active in vitro against gonococci, and clinical studies of some of these agents have been undertaken. Ciprofloxacin, given as a single 250-mg oral dose, cured 57 cases of gonorrhea, including 7 rectal and 3 pharyngeal infections (12) . Norfloxacin given orally in two 600-mg doses 4 h apart cured all of 59 cases of gonococcal urethritis, eliminating the nasopharyngeal colonization encountered in two patients (6) . Very promising are the low MICs of A-56619 against C. trachomatis. Poor results were observed in a clinical trial performed by one of us (R.C.B.) using 500 mg of ciprofloxacin twice daily for 2 days for the treatment of chlamydial urethritis. A 2-day treatment for chlamydial infections may be unrealistically short in view of the relatively long generation time of this organism. However, the eightfold-lower MICs of A-56619 should make this agent more suitable for treatment of these infections. In another clinical trial performed by one of us (R.C.B.), 47 of 49 chancroid infections were cured by a single 500-mg dose and all of 48 were cured by a single 1,000-mg dose of ciprofloxacin. In this in vitro study, A-56619 and A-56620 were more active than ciprofloxacin against H. ducreyi.
Pharmacokinetic studies in humans have been performed with some of the quinolones. Ciprofloxacin produces peak levels in serum ranging from 0.42 to 4.2 mg/liter after single oral doses of 250 and 1,000 mg, respectively (19) . In animal studies, A-56619 produced higher levels in serum (7) . After oral administration of 100 mg of A-56619, A-56620, and norfloxacin per kg to mice, levels in serum of 22.4, 4.5, and 1.2 ,ug/ml, areas under the curve of 207.3, 165.3, and 41.37 ug * h/ml, and half-lives of 10.9, 2.6, and 1.8 h, respectively, were demonstrated (7) .
The quinolones demonstrated poor activity against G. vaginalis. However, G. vaginalis infections respond well to treatment with metronidazole as a result of its activity on anaerobes, and because A-56619 and A-56620 demonstrate reasonable activity against anaerobic bacteria they may be appropriate for the treatment of Gardnerella-associated vaginosis (2). We found most U. urealyticum strains tested to be resistant to the quinolones. Although lower MICs of ciprofloxacin against U. urealyticum have been reported (14) , similar MIC ranges have also been documented (1, 8, 17) .
A-56619 was very active in vitro against gonococci, C. trachomatis, M. hominis, and H. ducreyi. With its good pharmacokinetic profile, A-56619 should prove useful in the treatment of sexually transmitted diseases, provided it proves to be nontoxic in humans.
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